FDA panel recommends approval of Pfizer’s Covid vaccine

CrisisInvesting

FDA panel recommends approval of Pfizer’s Covid vaccine for emergency use
PUBLISHED THU, DEC 10 20205:37 PM EST
Berkeley Lovelace Jr.
@BERKELEYJR
KEY POINTS
The full FDA could grant emergency use authorization of Pfizer’s vaccine as early as Friday.
The Vaccines and Related Biological Products Advisory Committee plays a key role in approving flu and other vaccines in the U.S.
The FDA doesn’t have to follow the advisory committee’s recommendation, but the agency often does.

Maylin

我有一把pfe..嘻嘻。。长持。。还有股息拿。。

CrisisInvesting

Maylin 发表于 2020-12-10 11:10 PM
我有一把pfe..嘻嘻。。长持。。还有股息拿。。

历害！能拿住的都不是一般2般的人。

Maylin

CrisisInvesting 发表于 2020-12-11 06:18 AM
历害！能拿住的都不是一般2般的人。

36 就买入了

阿方

CrisisInvesting

Kuwait has granted emergency use for the Pfizer vaccine.

CrisisInvesting

Mexico becomes 4th country to approve Pfizer-BioNTech coronavirus vaccine

阿方

CrisisInvesting

Francesco Guarascio
Thu, December 17, 2020, 2:15 AM PST
* EU to exercise option for up to 100 mln more Pfizer shots

* EU declined in July Pfizer offer for 500 mln doses - document

* EU has ordered 200 mln doses so far, jab approval due next week

- ADVERTISEMENT -

By Francesco Guarascio

BRUSSELS, Dec 17 (Reuters) - The European Union will take up its option to buy up to 100 million more doses of Pfizer and BioNTech's COVID-19 vaccine after turning down an opportunity in July for a much bigger deal, according to EU officials and an internal document.

The plan comes after some of the vaccine candidates ordered by the EU faced unexpected delays in clinical trials, forcing the bloc and other wealthy nations to rely for now on shots from fewer manufacturers than initially planned.

The Pfizer/BioNTech shot, the first COVID-19 vaccine to be approved by Western drugs regulators, is being rolled out in countries including Britain and the United States, and is expected to be approved for use in the EU next week.

The European Commission decided on Tuesday to exercise its option to buy up to 100 million additional doses under an existing contract with Pfizer and BioNTech, a spokesman for the EU executive told Reuters on Thursday. Under the same contract it has already ordered 200 million doses.

"We want to be sure to get more doses because there is big demand," the spokesman said.

An EU official said talks were underway over how many of the extra 100 million doses might be taken.

Pfizer did not respond to a request for comment. BioNTech declined to comment.

Under the EU contract, the two firms have committed to rapidly deliver 200 million doses after regulatory approval for 15.5 euros ($18.8) apiece, EU officials told Reuters in November.

The extra 100 million doses would be supplied at the same price, but with the timetable to be negotiated, EU officials said.

Pfizer and BioNTech have said they can produce about 1.3 billion doses by the end of 2021, but they are trying to expand manufacturing capacity as global demand surges.

CrisisInvesting

NEWARK, Del. (AP) — President-elect Joe Biden on Monday received his first dose of the coronavirus vaccine on live television as part of a growing effort to convince the American public the inoculations are safe.

The president-elect took a dose of Pfizer vaccine at a hospital not far from his Delaware home, hours after his wife, Jill Biden, did the same. The injections came the same day that a second vaccine, produced by Moderna, will start arriving in states. It joins Pfizer’s in the nation’s arsenal against the COVID-19 pandemic, which has now killed more than 317,000 people in the United States and upended life around the globe.

“I’m ready,” said Biden, who was administered the dose at a hospital in Newark, Delaware, and declined the option to count to three before the needle was inserted into his left arm. “I’m doing this to demonstrate that people should be prepared when it’s available to take the vaccine. There’s nothing to worry about.”

CrisisInvesting

Pfizer: A promising growth and dividend play
Pfizer is arguably another oddball pick as a "must-own" stock for 2021. After all, the pharmaceutical giant has lagged well-behind both the broader markets, as well as the biopharmaceutical industry, in terms of its total returns on capital over the past two decades. Its lackluster performance over this period has been due to a unfavorable mix of never-ending patent expires, along with management's snail-like response to the various challenges presented by generic competition.  

Pfizer, though, finally appears to be nearing an inflection point. The reason being is that the pharma titan has been busy streamlining its operations over the past two years by repackaging underperforming segments like Consumer Healthcare and off-brand legacy products. These savvy business development moves should thus allow newer growth products -- such as the breast cancer drug Ibrance, the blood thinner Eliquis, and the ATTR-cardiomyopathy medicine Vyndaqel --  to shine more brightly as the new decade unfolds.

Pfizer, in fact, is forecasting a compound annual growth rate for its top-line of 6% over the period covering 2021 to 2025 -- and that's not even including the potential windfall from its groundbreaking COVID-19 vaccine. What's more, Pfizer's stock is currently trading at an attractive 12.5 times forward-looking earnings, and it offers a rather healthy dividend yield for a mega-cap pharma stock.

All told, this big pharma stock seems poised for a banner 2021, thanks to its noteworthy growth prospects, compelling valuation, and outstanding dividend program.